Malat1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing mir-203 and promoting thymidylate synthase expression
文献类型：期刊论文
| 作者 | Chen, Wei1,2,3; Xu, Xin-Ke1; Li, Jun-liang1,2; Kong, Kuan-kei1,2; Li, Hui4; Chen, Cheng1; He, Jing1; Wang, Fangyu1; Li, Ping1; Ge, Xiao-song5 |
| 刊名 | Oncotarget
 |
| 出版日期 | 2017 |
| 卷号 | 8期号:14页码:22783-22799 |
| ISSN号 | 1949-2553 |
| 关键词 | Malat1 Temozolomide Chemoresistance Mir-203 Thymidylate synthase |
| DOI | 10.18632/oncotarget.15199 |
| 通讯作者 | Ge, xiao-song(stanly8345@163.com) ; Li, fang-cheng(sjwklfc@126.com) |
| 英文摘要 | Glioblastoma multiforme (gbm) is the most malignant brain tumor with limited therapeutic options. temozolomide (tmz) is a novel cytotoxic agent used as first-line chemotherapy for gbm, however, some individual cells can't be isolated for surgical resection and show treatment-resistance, thus inducing poor prognosis. by using the hiseq sequencing and bioinformatics methods, we identified lncrnas showing different expression levels in tmz-resistant and non-resistant patients. rt-qpcr was then performed in tissues and serum samples, and lncrna malat1 was finally identified to show considerable discriminating potential to identify responding patients from non-responding patients. moreover, high serum malat1 expression was associated with poor chemoresponse and survival in gbm patients receiving tmz treatment. subsequently, the tmz resistant cell lines were established, and the cck8 assay showed that lncrna malat1 knockdown significantly reversed tmz resistance in gbm cells. the gain and loss-function experiments revealed that mir-203 was downregulated by malat1 and this interaction has reciprocal effects. besides, thymidylate synthase (ts) mrna was identified as a direct target of mir-203. lncrna malat1 inhibition re-sensitized tmz resistant cells through up-regulating mir-203 and downregulating ts expression. on the other hand, malat1 overexpression promoted resistance by suppressing mir-203 and promoting ts expression. in conclusion, our integrated approach demonstrates that enhanced expression of lncrna malat1 confers a potent poor therapeutic efficacy and inhibition of malat1 levels could be a future direction to develop a novel therapeutic strategy to overcome tmz resistance in gbm patients. |
| WOS关键词 | NONCODING RNA MALAT1 ; COLORECTAL-CANCER CELLS ; DOWN-REGULATION ; MESENCHYMAL TRANSITION ; OXALIPLATIN RESISTANCE ; BRAIN-TUMORS ; STEM-CELLS ; GLIOMA ; PROLIFERATION ; TRANSCRIPTOME |
| WOS研究方向 | Oncology ; Cell Biology |
| WOS类目 | Oncology ; Cell Biology |
| 语种 | 英语 |
| 出版者 | IMPACT JOURNALS LLC |
| WOS记录号 | WOS:000398211100042 |
| URI标识 | http://www.irgrid.ac.cn/handle/1471x/2373448 |
| 专题 | 武汉病毒研究所 |
| 通讯作者 | Ge, Xiao-song; Li, Fang-cheng |
| 作者单位 | 1.Guangzhou Med Univ, Dept Neurosurg, Guangzhou Women & Childrens Med Ctr, Guangzhou 510623, Guangdong, Peoples R China 2.Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurosurg, Guangzhou 510120, Guangdong, Peoples R China 3.Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China 4.Sun Yat Sen Univ, Peoples Hosp Foshan 1, Dept Resp, Foshan 528000, Guangdong, Peoples R China 5.Jiangnan Univ, Dept Oncol, Affiliated Hosp, Wuxi 214062, Jiangsu, Peoples R China |
| 推荐引用方式 GB/T 7714 | Chen, Wei,Xu, Xin-Ke,Li, Jun-liang,et al. Malat1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing mir-203 and promoting thymidylate synthase expression[J]. Oncotarget,2017,8(14):22783-22799. |
| APA | Chen, Wei.,Xu, Xin-Ke.,Li, Jun-liang.,Kong, Kuan-kei.,Li, Hui.,...&Li, Fang-cheng.(2017).Malat1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing mir-203 and promoting thymidylate synthase expression.Oncotarget,8(14),22783-22799. |
| MLA | Chen, Wei,et al."Malat1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing mir-203 and promoting thymidylate synthase expression".Oncotarget 8.14(2017):22783-22799. |
入库方式： iSwitch采集
来源：武汉病毒研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。